Oral Spironolactone versus Conservative Treatment for Non-Resolving Central Serous Chorioretinopathy in Real-Life Practice.

Clin Ophthalmol · 2020 · PMC7322117 · PMID 32612347

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep =0.06so close (0.05 < p ≤ 0.1)

Although patients with 100% reduction of SRF height in the treatment group were much more than those in the control group, the overall SRF height reduction from baseline to 6 months between both groups did not reach statistical significance ( p =0.06) ( Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.